Sector News

Philips taps BioIntelliSense’s symptom-tracking sticker for COVID-19, other chronic diseases

July 13, 2020
Life sciences

Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs, designed to observe at-risk patients after they head home from the hospital.

BioIntelliSense debuted this past January, with an FDA-cleared multisensor patch capable of logging not just vital signs, but symptoms—including individual events such as sneezes, coughs and vomiting.

Philips plans to use the company’s BioSticker, with its 30-day battery life, to help monitor people with chronic conditions such as diabetes, cancer and heart failure, as well as to support its telehealth programs. This also includes keeping clinicians connected with COVID-19 patients who may not require hospitalization, while watching for signs of deterioration.

“With more patients interacting with their doctors from home and more hospitals developing strategies to virtually engage with their patients, remote patient monitoring is now, more than ever, an essential tool,” said Roy Jakobs, who was named chief business leader for Philips’ connected care offerings earlier this year.

By monitoring signs such as skin temperature, pulse, respiratory rate, overall activity level and the frequency of coughs, Philips hopes the system can trigger earlier interventions in people quarantined at home with the coronavirus.

“Multi-parameter sensors are the natural next phase for remote monitoring, especially at a time when more patients are engaging with their physicians from home,” said James Mault, founder and CEO of BioIntelliSense.

“Clinicians need medical-grade monitoring and algorithmic clinical insights for COVID-19 exposure, symptoms and management,” Mault said. “Accelerated by the COVID-19 crisis, the practice of medicine has been irreversibly enlightened as to the safety and efficacy of virtual care.”

Under the collaboration, the BioSticker will first be used by the U.S. service provider Healthcare Highways across seven monitoring programs, including aimed at COVID-19. The others will focus on heart failure, high blood pressure, diabetes, total joint replacement, cancer and asthma.

Meanwhile, Philips also announced a 10-year contract worth up to $100 million with the U.S. Department of Veterans Affairs, to expand its tele-ICU and connected critical care programs, as well as work in diagnostic imaging, sleep solutions and remote patient monitoring.

The VA manages 1,800 ICU beds nationwide, but—like much of the industry—has greatly expanded its telehealth work during the COVID-19 pandemic. From February to May, the VA’s number of video-to-home appointments exploded from about 10,000 up to 120,000 per week.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach